ModifiedBlue Cross Blue Shield - MassachusettsPolicy 572

GLP-1 and GLP-1/GIP Agonists for Chronic Weight Management and Related Indications

This policy governs prior authorization, medical necessity criteria, and continuation requirements for specified GLP-1 and GLP-1/GIP medications (e.g., liraglutide/Saxenda, semaglutide/Wegovy, tirzepatide/Zepbound) used for chronic weight management and related indications for BCBSMA commercial formularies.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyGLP-1 and GLP-1/GIP Agonists for Chronic Weight Management and Related Indications

Policy CodePolicy 572

Change TypeCriteria clarifiedagents addedcoverage limits updated

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization requests to BCBSMA Pharmacy Operations with baseline BMI/weight, documentation of a 6-month lifestyle trial, and required supporting clinical records.

SourceLink

POLICY UPDATE CHANGES

Effective 1/1/2026 coverage of GLP-1 and GLP-1/GIP agonists is not a covered benefit for members with the BCBSMA Focused Formulary and the medical necessity review process is not available for those members.

Initial approval and continuation criteria (including BMI thresholds, pediatric specifications, 6-month lifestyle trial, and weight-loss response thresholds) are specified for liraglutide, semaglutide (oral and subcutaneous), and tirzepatide.

Coverage limits: approvals are limited to 6 months initially and 12 months for continuation; fills restricted to a 1-month supply with 75% of days exhausted prior to refill; excluded from mail order.

Updated criteria to include high dose Wegovy injection and added oral semaglutide; revised title and moved non-GLP1 anti-obesity agents (Contrave, Imcivree) to a different policy and added generic liraglutide.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Initial Therapy - Liraglutide (Saxenda)

Covered when ALL of the following are met for liraglutide/Saxenda

Liraglutide initial criteria: 1) Use for chronic weight management in ONE of: (a) patient age 12–17 with body weight > 60 kg (must include baseline BMI, baseline weight, and BMI%); OR (b) adults with initial BMI ≥ 30 kg/m2; OR (c) adults with initial BMI ≥ 27 kg/m2 with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)see BMI thresholds

Lifestyle trial: 2) Physician attestation or documentation of a 6-month trial of a comprehensive weight loss plan (reduced-calorie diet, increased physical activity, behavioral modifications) prior to initiation of therapy6 months

Adjunct use: 3) Physician attestation or documentation that medication will be used as an adjunct to a comprehensive weight management plan including reduced-calorie diet, increased physical activity, and behavioral modifications

Step requirement: 4) For liraglutide requests: prior use of preferred drugs and failure or clinical rationale for not using preferred medications (Quality Care Dosing applies)

Continuation Therapy - Liraglutide

Continuation criteria for liraglutide/Saxenda

Response: 1) Documentation of significant weight loss by meeting ONE of: (a) ≥4% of baseline body weight after initiation (first 16 weeks); OR (b) continued weight loss; OR (c) maintenance of plateau weight achieved with diet/exercise>=4% at 16 weeks OR continued/maintenance

Adherence and tolerability: 2) Documentation that patient is adherent to therapy and has been tolerating the recommended maintenance dose for at least 3 consecutive months3 months

Ongoing lifestyle: 3) Documentation of continued engagement in a comprehensive weight management plan (reduced-calorie diet, increased physical activity, behavioral modifications)

Initial Therapy - Wegovy (oral and subcutaneous)

Covered when ALL of the following are met for Wegovy (semaglutide) — initial, MACE risk reduction, and MASH indications described separately

Population for use: 1) Use for chronic weight management in ONE of: (a) adults with initial BMI ≥ 30 kg/m2; OR (b) adults with initial BMI ≥ 27 kg/m2 with at least one weight-related comorbid condition; OR (c) for subcutaneous Wegovy ONLY: age 12–17 with initial BMI at or above the 95th percentile for age and gender (must include baseline BMI, baseline weight, and BMI%)see BMI thresholds

Wegovy tablets and Wegovy HD are FDA approved only for adults

Adjunct use: 3) Physician attestation or documentation that medication will be used as an adjunct to a comprehensive weight management plan

Wegovy for MACE risk reduction

MACE risk-reduction indication for Wegovy

Population: 1) Patient is age ≥45 years; AND 2) BMI > 27 kg/m2; AND 3) other trial-specific criteria as listed in the clinical record (e.g., established cardiovascular disease where applicable)age >=45; BMI >27

Wegovy HD is NOT FDA approved for MACE risk reduction

Wegovy for MASH

MASH indication for subcutaneous Wegovy only

Diagnosis: 1) Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2–F3) confirmed by ONE of: vibration-controlled transient elastography (VCTE), magnetic resonance elastography (MRE), or historical liver biopsyF2–F3

Wegovy tablet and Wegovy HD are NOT FDA approved for MASH

Lifestyle engagement: 2) Physician attestation or documentation that the member is actively engaged in a comprehensive lifestyle modification plan (reduced-calorie diet, increased physical activity, behavioral modifications) prior to initiation

Patient must be on FDA‑approved maintenance dose for MASH indication

Continuation Therapy - Wegovy

Continuation criteria for Wegovy

Maintenance dose: 1) Patient is on the FDA‑approved maintenance dose: Wegovy injection in adults (1.7 mg, 2.4 mg, or 7.2 mg listed) or Wegovy oral tablet 25 mg; pediatric injection doses 1.7 mg or 2.4 mg as applicablespecific maintenance doses noted

Response: 2) Documentation of significant weight loss by meeting ONE of: (a) ≥5% of baseline body weight after initiation (first 16 weeks); OR (b) continued weight loss; OR (c) maintenance of plateau weight achieved with diet/exercise>=5% at 16 weeks OR continued/maintenance

Adherence: 3) Documentation that patient is adherent and tolerating the recommended maintenance dose for at least 3 consecutive months; for MACE indication adherence may be defined as >80% fill rate evidenced by claims3 months; >80% fill rate for MACE continuation

Initial and Continuation Therapy - Zepbound

Covered when ALL of the following are met for Zepbound (tirzepatide)

Age: 1) Member is 18 years of age or older>=18 years

Lifestyle trial: 2) Documentation of at least a 6-month trial of a comprehensive weight loss plan (reduced-calorie diet, increased physical activity, behavioral modifications) prior to initiation6 months

Adjunct use: 3) Physician attestation/documentation that medication will be used as an adjunct to a comprehensive weight management plan

BMI criteria: 4) For chronic weight management meet ONE: (a) initial BMI ≥ 30 kg/m2; OR (b) initial BMI ≥ 27 kg/m2 with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)

Initial Authorization

Covered when ALL of the following are met

Initial authorization: 1) Physician attestation/documentation that medication will be used as an adjunct to a comprehensive weight management plan (reduced-calorie diet, increased physical activity, behavioral modifications); AND 2) Patient meets ONE of: initial BMI ≥ 30 kg/m2 OR initial BMI ≥ 27 kg/m2 with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).

Continuation Therapy (Zepbound)

May renew coverage if ALL of the following are met

Continuation for Zepbound: 1) Patient is on the 5 mg, 10 mg, or 15 mg dose; 2) Documentation of significant weight loss by meeting ONE of: (a) ≥5% of baseline body weight after initiation (first 20 weeks); OR (b) continued weight loss; OR (c) maintenance of plateau weight achieved with diet/exercise; 3) Documentation that the patient is adherent to therapy and has been tolerating the recommended maintenance dose for at least 3 consecutive months; 4) Documentation that the patient continues a comprehensive weight management plan including reduced-calorie diet, increased physical activity, and behavioral modifications.

For members whose benefits are governed by the BCBSMA Focused Formulary, GLP‑1 and GLP‑1/GIP medications for obesity and other FDA‑approved indications are not a covered benefit. The medical necessity review process is not available for these members, and prior authorization requests for these agents will be denied.

Effective 1/1/2026, the policy includes benefit exclusions and administrative updates: certain non‑GLP‑1 anti‑obesity agents were moved to a different policy, discontinued agents were removed, oral semaglutide was added, high‑dose Wegovy injection criteria were updated, and generic liraglutide was added. See the policy history for the complete list of changes and the effective date of the exclusions.

Coverage under this policy applies only to members who have benefit coverage for these medications under the BCBSMA formulary. For members on the BCBSMA Focused Formulary, GLP‑1 and GLP‑1/GIP agents for obesity and other FDA‑approved indications are specifically excluded from coverage and cannot be approved through the medical necessity review process.

Requests submitted based solely on the provision or prior use of samples will not meet the coverage criteria for an exception. Providers must submit additional supporting clinical documentation demonstrating medical necessity (for example, chart notes, labs, prior treatment history) to allow individual consideration of the request.

Covered Agents, Codes, and Eligibility Thresholds

Covered agents by name in policymixedCovered

liraglutide	liraglutide (Saxenda)
semaglutide	Wegovy (oral and subcutaneous)
tirzepatide	Zepbound

References (drugs mentioned)mixed

N/A	Package insert references for Saxenda, Wegovy, Zepbound cited in references

BMI thresholds for initiation — adults and pediatric eligibility thresholds

Adult BMI thresholdBMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes)

Pediatric — Liraglutide (Saxenda)Ages 12–17 with body weight >60 kg (must include baseline BMI, baseline weight, and BMI % for pediatrics)

Pediatric — Wegovy (subcutaneous)Ages 12–17 with initial BMI at the 95th percentile or greater (must include baseline BMI, baseline weight, and BMI % for pediatrics)

Age requirement — Zepbound (tirzepatide)Patient must be 18 years of age or older for Zepbound initial approval

Early weight-loss response thresholds

Liraglutide early response (16 weeks)

Prior Authorization, Documentation, and Prescriber Responsibilities

Prior Authorization

Prior Authorization Required

Prior Authorization Required — Prior authorization is required for all GLP‑1 and GLP‑1/GIP agents under this policy. Requests must be submitted to BCBSMA Pharmacy Operations (see contact details) prior to dispensing. Initial approvals are generally for 6 months; continuation approvals for 12 months. Coverage is limited to a 1‑month supply per fill (28–30 days) and 75% of days must be exhausted before refill. Mail order is excluded for these agents.

Submit requests to: Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department, 25 Technology Place, Hingham, MA 02043
Tel: 1-800-366-7778; Fax: 1-800-583-6289
Use Massachusetts Standard Form for Medication Prior Authorization Requests (eForm) or the printed/formulary exception form

Denial Risk

Focused Formulary Exclusion

Focused Formulary Exclusion — Members on the BCBSMA Focused Formulary do NOT have coverage for GLP‑1 and GLP‑1/GIP agonists for obesity or other FDA‑approved indications. For these members the medical necessity review process is not available and requests will be denied.

Key Clinical Definitions

MACE — major adverse cardiovascular events defined

DefinitionMajor adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke

MACE indication age/BMIFor Wegovy MACE risk-reduction indication: patient must be ≥45 years old and have BMI >27

Wegovy HD noteWegovy HD is NOT FDA approved for reduction in risk of MACE

MASH — metabolic dysfunction-associated steatohepatitis definition and fibrosis staging

TermMetabolic dysfunction-associated steatohepatitis (MASH), previously noncirrhotic NASH

Fibrosis staging requiredModerate to advanced liver fibrosis consistent with stages F2–F3 confirmed by VCTE, MRE, or historical liver biopsy

Background and Scope

GLP‑1 and GLP‑1/GIP agonists (for example, liraglutide, semaglutide, and tirzepatide) are pharmacologic treatments used as adjuncts to comprehensive lifestyle interventions for chronic weight management in adults and select pediatric populations. The policy describes agent‑specific eligibility criteria including baseline BMI thresholds, a required 6‑month trial of a comprehensive weight‑loss program prior to initiation, and predefined early weight‑loss response thresholds that determine continuation. Additionally, certain formulations have indication‑specific uses (for example, subcutaneous semaglutide for MASH and select formulations for MACE risk reduction), and the policy was updated to add oral semaglutide and high‑dose Wegovy injection effective in the 2026 revisions.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyGLP-1 and GLP-1/GIP Agonists for Chronic Weight Management and Related Indications

Policy CodePolicy 572

Change TypeCriteria clarifiedagents addedcoverage limits updated

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionSubmit prior authorization requests to BCBSMA Pharmacy Operations with baseline BMI/weight, documentation of a 6-month lifestyle trial, and required supporting clinical records.

SourceLink

On This Page

Documentation Required

Required Clinical Documentation

Required Clinical Documentation — Submit documentation to show all clinical criteria are met. Include baseline and pediatric specifics, and physician attestations for lifestyle trial and adjunctive use.

Baseline adult BMI and weight; for pediatrics include baseline BMI, baseline weight, and BMI percentile for age/gender
Physician attestation/documentation of a 6‑month trial of a comprehensive weight‑loss plan (reduced‑calorie diet, increased physical activity, behavioral modifications) prior to initiation
Physician attestation that medication will be used as an adjunct to a comprehensive weight management plan
For liraglutide: documentation of previous use of preferred drugs or clinical rationale for not using preferred medications

Documentation Required

Continuation Documentation

Continuation Documentation — For renewal requests provide documentation of adherence, tolerability on the maintenance dose, and clinical response as specified in the policy. Renewal approvals require evidence the member meets drug‑specific continuation criteria.

Document patient is on FDA‑approved maintenance dose (e.g., Wegovy injection 1.7 or 2.4 mg in pediatrics; adult maintenance doses per policy; Zepbound 5, 10, or 15 mg)
Provide evidence of adherence and tolerating the maintenance dose for at least 3 months where applicable
Provide weight‑loss response documentation as required by the specific agent’s continuation criteria

Documentation Required

Required Supporting Documentation

Required Supporting Documentation and Samples — Provide supporting clinical records with the PA: chart notes, lab results, and specific documentation of prior trials or contraindications. Requests based solely on sample use will not meet coverage criteria.

Include chart notes, labs, and other clinical information demonstrating medical necessity
If non‑formulary/non‑covered agents are requested, include names, strengths, and details of formulary alternatives tried and specifics regarding treatment failures or contraindications
Requests based exclusively on samples will be denied; additional clinical information must be submitted

Step Therapy

Quality Care Dosing / Step Requirements

Quality Care Dosing and Step Requirements — Quality Care Dosing (QCD) applies to affected agents and prior use of preferred agents or documented rationale for not using them is required where specified (e.g., liraglutide). Follow step/quality care dosing expectations in formulary status table.

Quality Care Dosing applies to Liraglutide, Saxenda, Wegovy (oral and subcutaneous), and Zepbound
For agents listed as non‑formulary/non‑preferred, document prior failure of preferred formulary alternatives or clinical rationale for bypassing them

Note

Formulary Alternatives and Exceptions

Formulary Alternatives and Exceptions — When a non‑formulary or non‑preferred medication is requested, document trials of formulary alternatives or contraindications. Higher member cost‑share may apply for approved non‑preferred/non‑formulary exception requests.

For non‑covered medications, member must have previous treatment failure with, or contraindication to, at least two covered formulary alternatives when available
If approving a non‑preferred/non‑formulary exception, a higher cost‑share may be applied
Include clinical literature or compendia references for individual consideration when appropriate

BMI eligibility — chronic weight management patient eligibility summary

Chronic weight management adult eligibilityAdults with initial BMI ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related comorbidity

Pediatric eligibility — LiraglutideAges 12–17 with body weight >60 kg (must include baseline BMI, weight, and BMI %)

Pediatric eligibility — Wegovy injectionSubcutaneous Wegovy in ages 12–17 with initial BMI ≥95th percentile for age and gender (must include baseline BMI, weight, and BMI %)

Age requirement — ZepboundZepbound initial approval requires patient age ≥18 years